Meglumine antimoniate

Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]

Meglumine antimoniate
Clinical data
Other namesMeglumine antimonate
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.004.645
Chemical and physical data
FormulaVariable
Molar massVariable
3D model (JSmol)
 NY (what is this?)  (verify)

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[4] It is available in Southern Europe and Latin America but not the United States.[5][6]

Society and culture

It is manufactured by Aventis[7] and sold as Glucantime in France, and Glucantim in Italy.

See also

References
  1. WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  2. Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
  3. "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  4. "Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
  5. Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. Archived from the original on 2016-12-20.
  6. Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
  7. Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.